Reimbursement can be challenging because these are early days of something new and revolutionary. Science and technology advancements are occurring at exponential rates. Healthcare is still moving at more of a linear step-wise fashion. Sometimes payers will decline coverage because they feel there isn’t enough data to determine the clinical utility of these tests. What’s maddening is that as an industry we won’t be able to generate enough data if we don’t start covering the costs of these clinically validated tests. Catch 22. We need to collectively fix this!
KEEP UP WITH WHAT’S HAPPENING
BLOG
JOIN THE MOVEMENT - STAY IN TOUCH
Sign up for email updates and news from SequenceMe.
Recent Posts
Latest Tweets
[twit_stream id="2"]